, Volume 120, Issue 2, pp 128–133 | Cite as

Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability

  • D. C. Hoffman
  • H. Donovan
Original Investigation


The predictive validity of catalepsy as a rodent model for detecting the extrapyramidal side effects (EPS) of antipsychotic drugs was recently questioned when the novel antipsychotic savoxepine produced little catalepsy in rodents while producing significant EPS in schizophrenic patients. Because catalepsy is viewed as an important model for predicting EPS, we decided to re-evaluate the effects of savoxepine. Savoxepine, clozapine, haloperidol, olanzapine, ORG 5222, raclopride, and risperidone were examined in two tests for catalepsy (grid and bar tests) in male Sprague-Dawley rats. The ability to antagonize amphetamine-induced hypermotility was also examined, since this measure is believed to predict clinical efficacy. With the exception of clozapine, all drugs produced dose-dependent catalepsy in both tests. For each drug, the minimum effective dose for producing catalepsy was greater than or equal to the ED50 for antagonizing amphetamine-induced hyperactivity (defined as the dose producing a 50% reduction in hyperactivity). Clozapine resulted in the widest separation of effective doses in the catalepsy and activity models. Raclopride produced the next largest separation while the remaining drugs resulted in only a one-or two-fold dose separation between the two behavioral tests. The results with haloperidol and clozapine are consistent with the clinical effects of these drugs (severe versus mild EPS). The ratios of effective doses in catalepsy and activity for the remaining novel drugs are also consistent with preliminary clinical findings indicating some EPS with each of these compounds. Thus, catalepsy remains a suitable rodent model for detecting compounds with EPS liability in humans.

Key words

Catalepsy Rodent model Antipsychotic drugs Extrapyramidal side effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321–329Google Scholar
  2. Arnt J, Christensen AV (1981) Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. Eur J Pharmacol 69:107–111Google Scholar
  3. Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's the pharmacological basis of therapeutics. Pergamon Press, New York, pp 383–435Google Scholar
  4. Bischoff S (1992) Towards the understanding of the neuroanatomical substrate of schizophrenia: The contribution of savoxepine. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 117–134Google Scholar
  5. Broekkamp CLE, DeGraaf JS, van Delft AML (1990) Behavioral pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b,tetrahydro-1H-dibenz[2, 3: 6, 7]oxepino-[4, 5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40:544–549Google Scholar
  6. Bugarski-Kirola D, Bokonjic D, Rosic N, Paunovic VR (1994) Behavioral effects of savoxepine in rats. Neuropsychopharmacology 10:110SGoogle Scholar
  7. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53Google Scholar
  8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, LaBelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40Google Scholar
  9. Costall B, Naylor RJ (1973) Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung 23:674–683Google Scholar
  10. Farde L, Nordstrom A, Wiesel F, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538–544Google Scholar
  11. Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AHP, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693Google Scholar
  12. Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry [Suppl] 17:38–40Google Scholar
  13. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835Google Scholar
  14. McCreadie RG (1992) A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. Acta Psychiatr Scand 86:391–398Google Scholar
  15. McInerney SC, Hoffman DC, Donovan H, Cornfield RJ, Meade RJ, Cassella JV, Gallager DW (1994) Effects of antipsychotics on the pentylenetetrazole (PTZ) seizure threshold relative to in vivo potency may be predictive of clinical seizure liability. Soc Neurosci Abstr 20:1772Google Scholar
  16. Moller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G (1989) Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot study. Pharmacopsychiatry 22:38–41Google Scholar
  17. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262:545–551Google Scholar
  18. Morelli M, DiChiara G (1985) Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol 117:179–185Google Scholar
  19. Ogren SO, Hall H, Kohler C, Magnusson O, Sjostrand S (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287–294Google Scholar
  20. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102:748–759Google Scholar
  21. Seeman P (1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261–284Google Scholar
  22. Sitsen JMA, de Vries MCV (1992) ORG 5222: Preliminary clinical results. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 15–18Google Scholar
  23. Waldmeier PC, Bischoff S, Bittiger H, Hauser K, Vassout A, Delini-Stula A, Haeusler A, Schenkel L, Storni A (1986) Pharmacological profiles of four new tetracyclic dopamine antagonists maroxepine, citatepine, eresepine, and cipazoxapine. Pharmacopsychiatry 19:316–317Google Scholar
  24. Wetzel H, Wiedemann K, Holsboer F, Benkert O (1991) Savoxepine: invalidation of an “atypical neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology 103:280–283Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • D. C. Hoffman
    • 1
  • H. Donovan
    • 1
  1. 1.Neurogen CorporationBranfordUSA

Personalised recommendations